Oreofe Odejide News Today

Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.

The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard care is, a new study shows.

TUESDAY, July 6, 2023 (HealthDay News) -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the

TUESDAY, July 6, 2023 (HealthDay News) -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the

TUESDAY, July 6, 2023 (HealthDay News) -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the

TUESDAY, July 6, 2023 (HealthDay News) -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the

TUESDAY, July 6, 2023 (HealthDay News) -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the

Therapy slows multiple myeloma in patients who have stopped responding to other treatments, say researchers

BioPharma

A treatment that involves genetically modifying the body's own immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type of blood cancer, results showed…